

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
22 March 2017 @ 0900 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004***

- **Administrative Meeting (BAP members only @ 7:45 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations for the following drugs/drug classes during the February 2017 meeting and interim meeting:

- ***Drug Class Reviews***
 - ***Hepatitis C Virus (HCV) Drugs—Direct-Acting Antivirals Subclass***
 - ***Antibiotics—Tetracyclines Subclass***
 - ***Proton Pump Inhibitors (PPIs) (Interim P&T Committee meeting)***
- ***Section 702 Drugs: Recently Approved Drugs—Abbreviated Reviews (Innovator Drugs)***
 - ***Basal Insulins: insulin glargine (Basaglar KwikPen)***
 - ***Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA): lixisenatide (Adlyxin)***
 - ***Glucagon-Like Peptide-1 Receptor Agonists (GLP1RA): lixisenatide/insulin glargine (Soliqua)***
 - ***Hepatitis B Agents: tenofovir alafenamide (Vemlidy)***
 - ***Ophthalmic-1 Nonsteroidal Anti-inflammatory Drugs (NSAIDS): bromfenac 0.075% ophthalmic solution (BromSite)***
 - ***Oral Oncology Agents: rucaparib (Rubraca)***
 - ***Vitamin D Analogs: calcifediol (Rayaldee)***
- ***Utilization Management Issues***
 - ***Prior Authorization Criteria***
 - ***Epinephrine Auto-Injectors***

- *Oral Oncology Agents: palbociclib (Ibrance)*
- *Anticonvulsant and Anti-Mania Drugs: topiramate ER (Trokendi)*
- *Testosterone Replacement Therapies*
- *Formulary Update*
 - *Antilipidemic-Is (LIPS-Is): rosuvastatin (Crestor)*
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.